¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"afferent pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • metabolic pathway
    ´ë»ç°æ·Î.
  • neurohumoral pathway
    ½Å°æ¾×¼º °æ·Î(~ÌèÖØ).
  • nigrostriatal pathway
  • oculomotor pathway
    ¾È±¸¿îµ¿½Å°æ·Î(äÑÏ¹ê¡ ÔÑãêÌèÖØ).
  • optic pathway
    ½Ã·Î.
  • optic pathway
    ½Ã½Å°æ·Î.
  • pain pathway
    Åë°¢Àü´Þ·Î(÷ÔÊÆîîÓ¹ÖØ).
  • pancreas,protein secertion pathway
    ´Ü¹éÁúºÐºñ°æ·Î(Ó±ÛÜòõÝÂÝôÌèÖØ)
  • parallel pathway
    (°¨°¢Á¤º¸Ã³¸®ÀÇ)ÆòÇà°æ·Î
  • pathway
    °æ·Î(ÌèÖØ).
  • pentose phosphate pathway
    ¿Àź´ç ÀλêÈ­ ¹ÝÀÀ
  • phosphogluconate oxidative pathway
    ±Û·çÄÜ»ê»êÈ­°æ·Î, ÀÎ´ç¿ø»êÈ­°æ·Î(ìÝÓØ ê«ß«ûùÌèÖØ).
  • proximal common pathway
    ±ÙÀ§°øÅë°æ·Î.
  • pyruvate pathway
    ÇÇ·çºê»ê¿°´ë»ç°æ·Î(¡­ß«ç¤ÓÛÞóÌèÖØ).
  • reflex path =r. pathway, r. tract
    ¹Ý»ç°æ·Î(ÚãÞÒÌèÖØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • salvage pathway
    ÀçÀÌ¿ë °æ·Î(î¢××éÄÌèÖØ)
  • shikimic acid pathway
    ½¬Å´»ê(ß«) °æ·Î(ÌèÖØ)
  • short patch pathway
    ´ÜÆí °æ·Î(Ó­ø¸ÌèÖØ)
  • succinate pathway
    ¼÷½Å»ê(ß«) °æ·Î(ÌèÖØ)
  • tiered metabolic pathway
    ÃþÃþ´ë»ç °æ·Î (öµöµÓÛÞóÌèÖØ)
  • Warburg-Dickens pathway
    ¹Ù¸£ºÎ¸£Å©-µðŲ½º °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
EMP electric membrane property; electromagnetic pulse; Embden-Meyerhof pathway; external membrane potent...
EPI echo planar imaging; electronic portal imaging; Emotion Profile Index; epilepsy; epinephrine; epithe...
FCP F-cell production; final common pathway; Functional Communication Profile
HMP hexose monophosphate pathway; hot moist packs
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TFPI Tissue Factor Pathway Inhibitor
TFPI-2 Tissue factor pathway inhibitor-2
APC alternative pathway of complement
FP fast pathway
GSP general secretory pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • afferent lymphatic vessel
    ¼öÀÔ ¸²ÇÁ°ü
    1. ¸²ÇÁÀý·Î µé¾î°¡´Â ¸²ÇÁ°üÀ» ¸»Çϸç, ¸²ÇÁÀýÀÇ º¼·Ï¸é¿¡¼­ ¿©·¯ °³°¡ À¯ÀÔÇÏ´Â °ÍÀÌ ÀϹÝÀûÀÌ´Ù. 2. Á¶Á÷¿¡¼­ ½º¸ç³ª¿Â ¸²ÇÁ´Â ¿©·¯ °³ÀÇ ¼öÀÔ ¸²ÇÁ°üÀ» ÅëÇÏ¿© ¸²ÇÁÀý¿¡ µé¾î°¡°í, ¼öÃâ ¸²ÇÁ°ü
  • afferent nerve
    ±¸½É¼º ½Å°æ, ±¸½É½Å°æ, ¼öÀԽŰæ
    1. ¸»ÃÊ¿¡¼­ ¾òÀº Á¤º¸¸¦ ½Å°æ°è¿¡ ÀüÇÏ´Â ½Å°æ. ´ëÇ¥ÀûÀ¸·Î ÇǺηκÎÅÍÀÇ ±¸½É½Å°æÀº ÃË, ¿Â, ³Ã, ¾ÐÅë µîÀÇ °¨°¢À» ÀüÇÑ´Ù. 2. °¨°¢ ¼ö¿ë±â·ÎºÎÅÍ ³ú, ô¼ö¸¦ ÇâÇØ ÀÓÆÞ½º¸¦ Àü´ÞÇÏ´Â ½Å°æ. 3. ¸»ÃÊ¿¡¼­ ÁßÃ߸¦ ÇâÇØ ÀÓÆÞ½º¸¦ º¸³»´Â ½Å°æ. ¿ø½É½Å°æ¿¡ ´ëÀÀÇÏ´Â °ÍÀ¸·Î °¨°¢½Å°æ°ú °°´Ù. °¨°¢¼¼Æ÷·ÎºÎÅÍ ³ª¿Í¼­ ô¼ö³ª ³ú·Î µé¾î°¡´Â ½Å°æÀε¥ °¨°¢¼¼Æ÷ÀÇ È°µ¿ »óŸ¦ ½Å°æÀÇ ÀÓÆÞ½º·Î½á Àü´ÞÇÑ´Ù.
  • afferent nociceptor
    ±¸½É¼º Ä§ÇØ ¼ö¿ëü, ±¸½É¼º À¯ÇØ ¼ö¿ë±â
  • afferent peripheral nerve
    ±¸½É¼º ¸»ÃʽŰæ
  • afferent system
    ±¸½É ½Å°æ°è
  • bile-duct afferent
    ±¸½É¼º ´ã°ü
  • C afferent
    C ±¸½É ½Å°æ
    °¡´Â ½Å°æ ¼¶À¯. Àü´Þ ¼Óµµ°¡ ºü¸£°í ÅëÁõÀ» Àü´ÞÇÑ´Ù.
  • C primary afferent nociceptor
    C ÀÏÂ÷ ±¸½É¼º Ä§ÇØ ¼ö¿ëü, C ÀÏÂ÷ ±¸½É¼º À¯ÇØ ¼ö¿ë±â
  • converging afferent interneuron
    ÁýÇÕ¼º ±¸½É¼º °³Àç ´º·±
  • cutaneous afferent
    ÇǺΠ±¸½É ½Å°æ
  • inhibitory afferent input
    ¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
  • myelinated afferent
    À¯¼öÃÊ ±¸½É ½Å°æ
  • myelinated afferent inhibition
    À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
  • myelinated cutaneous afferent
    À¯¼öÃÊ ÇǺΠ±¸½É ½Å°æ
  • myelinated non-nociceptive afferent
    À¯¼öÃÊ ºñÄ§ÇØ¼ö¿ë¼º ±¸½É ½Å°æ, À¯¼öÃÊ ºñÀ¯Çؼö¿ë¼º ±¸½É ½Å°æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 4
Embden-Meyerhof pathway The main pathway for anerobic degradation of carbohydrate. Starch or glycogen is hydrolysed to glucose 1 phosphate and then through a series of intermediates, yielding two ATP molecules per glucose and producing either pyruvate which feeds into the tricarboxylic acid cycle) or lactate.
(18 Nov 1997)
Entner-Douderoff pathway A degradative pathway for carbohydrates in certain microorganisms (e.g., Pseudomonas sp.) that lack hexokinase, phosphofructokinase, and glyceraldehyde-3-phosphate dehydrogenase.
(05 Mar 2000)
Entner-Doudoroff pathway <biochemistry> A pathway that converts glucose to pyruvate and glyceraldehyde-3 phosphate by producing 6-phosphogluconate and then dehydrating it.
(09 Oct 1997)
extrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
4-aminobutyrate pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
lysogenic pathway <virology> The method by which a virus becomes a dormant, passive part of its host bacterium's genome (a lysogenic virus), choosing to insert its DNA into the host's and postponing completion of its lytic cycle, at which time it destroys the host and spreads its progeny to infect other bacterial cells (enters the lytic pathway).
(09 Oct 1997)
lytic pathway The steps in the method that a virus takes to complete a lytic cycle, including the production and assembly of progeny viruses with host cell machinery and the destruction of the host cell by rupturing its plasma membrane (lysis), releasing the progeny viruses in the process.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á